Blood
Articles in this Issue
Five-year interim analysis of multi-institutional collaborative study for estimating the persistence of treatment free remission in chronic myeloid leukemia after stopping tyrosine kinase inhibitor in Japan: J-SKI
Abstract Introduction: Tyrosine Kinase Inhibitors (TKIs) have substantially improved survival outcomes for patients with chronic myeloid leu...
Limited-stage Mantle Cell Lymphoma: Real-world outcomes according to nodal vs. extranodal presentation
Abstract Introduction Mantle cell lymphoma (MCL) treatment has evolved significantly in recent years, with a paradigm shift from traditional...
At-211-anti-CD45 radioimmunotherapy as conditioning prior to haploidentical hematopoietic cell transplantation in mouse models
Abstract Background: Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment option for high-risk acute myel...
Molecular landscape and clonal evolution in minor versus major BCR::ABL1 chronic myeloid leukemia under tyrosine kinase inhibition : A Study from the french group fi-LMC
Abstract Background: Chronic myeloid leukemia (CML) is most commonly driven by the major BCR::ABL1 transcript (p210), while the minor BCR::A...
Knockdown of the long isoform of the prolactin receptor selectively targets pathogenic immune cells and averts lupus nephritis
Abstract Rationale: Systemic lupus erythematosus (SLE) is an autoimmune disease where pathologically activated B and other immune cells indu...
Mechanistic basis of the acute safety profile of rese-cel, an autologous CD19-CAR T, in patients with autoimmune disease treated in four ongoing phase 1/2 clinical trials
Abstract Introduction: Autologous CD19 CART therapies have been utilized across a wide range of B cell driven autoimmune diseases (AD), incl...
Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma
Abstract Background. ZUMA-12 (NCT03761056), a multicenter phase 2 study, evaluated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19...
Assessing patient-reported outcomes in Phase 3 multiple myeloma trials between 2020-2024 – a systematic review.
Abstract Introduction: Patient-reported outcomes (PROs) are valuable tools in clinical trials, providing crucial insights into treatment imp...
IFN-γ-induced CD4+ CADM1+ T cells emerged as malignancy-progressive biomarkers in EBV NK/T lymphoproliferative disorders and potential drivers of malignant expansion in AITL
Abstract Objective Epstein-Barr virus (EBV) infection of T and NK cells leads to EBV-associated NK/T-cell lymphoproliferative disorders (EBV...
Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium
Abstract Introduction: The GPRC5D-directed bispecific antibody (BsAb) Talquetamab (Talq) has shown promising results for patients (pts) with...
Cerebral hemodynamic changes during vaso-occlusive episodes in pediatric sickle cell disease
Abstract Introduction: Vaso-occlusive pain episodes (VOE) are one of the most common and debilitating complications in people with sickle ce...
From juvenile idiopathic arthritis to blastic plasmacytoid dendritic cell neoplasm: A diagnostic odyssey in a 14-year-old patient
Abstract Musculoskeletal symptoms can often present within a wide differential diagnosis in pediatrics, with juvenile idiopathic arthritis (...
A reverse vaccinology approach to development a multi-epitope vaccine candidate against multiple myeloma: An in-silico study
Abstract Multiple myeloma (MM) is a clonal plasma cell malignancy that remains largely incurable despite recent advances in therapies. As a...
Favorable survival and tolerability of the GMALL protocol in adolescents and young adults with ALL: A single-center experience
Abstract Background: Treatment of adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL)...
Immune population changes after glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with follicular lymphoma and marginal zone lymphoma
Abstract Introduction: Glofitamab (glofit) is a CD3xCD20 bispecific antibody that achieved high response rates but also...
Outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis using post-transplant cyclophosphamide-based gvhd prophylaxis
Abstract Background Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative therapy for myelofibrosis (MF), thoug...
The prognostic impact of MTHFR gene polymorphisms and p15 gene methylation in Myelodysplastic Syndromes
Abstract Introduction: Myelodysplastic syndromes (MDS) are clonal hematological neoplasms characterized by ineffective hematopoiesis and a r...
Review of the management of patients with immune thrombotic thrombocytopenic purpura with persistently low adamts-13 activity - a challenge beyond rarity.
Abstract INTRODUCTION: Immune thrombotic thrombocytopenic purpura (iTTP) is characterized by the presence of autoantibodies or an inhibitor...
Luspatercept for the treatment of myelodysplastic syndrome: A retrospective cohort study utilizing trinetx
Abstract Introduction Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders defined by ineffectiv...
Mechanism and therapeutic efficacy of the XPO1 inhibitor selinexor in refractory/relapsed EBV-positive NK cell lymphoma
Abstract Introduction: Refractory/relapsed Epstein-Barr virus (EBV)-positive NK cell lymphoma demonstrates poor response to existing therapi...
GMP compliant CRISPR/Cas9 gene editing of B2 microglobulin in cord blood derived megakaryocytes and platelets for patients with refractory thrombocytopenia
Abstract Introduction: A reliable and sustainable supply of platelets remains a critical challenge in managing thrombocytopenic patients, pa...
Trials in progress - A phase II study of pemigatinib in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (PERFORM)
Abstract Background: Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin lymphoma (NHL) with an aggressive disease course in the m...
Clonal hematopoiesis of indeterminate potential in coronary disease patients: A 24-year follow-up
Abstract Background: Cardiovascular disease is highly prevalent and remains a cause of great morbi-mortality worldwide. Growing evidence sug...
Clonal hematopoiesis is associated with the risk of Alzheimer's disease in the UK biobank apoe ε3/ε3 genotype cohort
Abstract The presence of a mutation with a variant allele fraction (VAF) of at least 2% in a gene associated with myeloid malignancies in bl...
Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study
Abstract Background Covalent and non-covalent Bruton's tyrosine kinase inhibitors (c/ncBTKis) are approved for the treatment of chronic lymph...